Streetbeat News

Stock Prices

SEEL

Seelos Therapeutics announced a 1-for-16 reverse stock split to regain compliance with Nasdaq's minimum bid price requirement. The split will be effective on September 27, 2024, and the stock will trade under the same symbol 'SEEL' with a new CUSIP number.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2024 | 12:18 pm

PCRX

DOMA Perpetual Capital Management has urged Pacira Biosciences to accelerate and increase its share buyback program, citing the company's $400 million cash balance as inefficient. They believe the current stock price presents an opportunity for significant shareholder returns.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2024 | 12:17 pm

BABA

GVIP

JTEK

LI

NVDA

XPEV

Alibaba's Apsara Conference showcased AI advancements with participation from Nvidia and XPeng. Despite US sanctions, Alibaba continues to push its AI initiatives and partnerships, including with XPeng and Nvidia. Alibaba's stock has risen over 11% in the past year.

Portfolio Pulse from Anusuya Lahiri

September 25, 2024 | 12:16 pm

WINT

Windtree Therapeutics announced positive topline results from its Phase 2B SEISMiC extension study of Istaroxime in early cardiogenic shock. The study showed significant improvements in systolic blood pressure over six hours and notable secondary endpoint improvements.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2024 | 12:10 pm

AVDL

Avadel Pharmaceuticals published data in 'Sleep Medicine' showing the efficacy of LUMRYZ in improving narcolepsy symptoms, regardless of alerting agent use. The Phase 3 REST-ON trial confirmed significant improvements in wakefulness and reduced cataplexy episodes.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2024 | 12:10 pm

ERAS

Erasca, Inc. (NASDAQ:ERAS) will present preliminary Phase 1 data for naporafenib plus trametinib in RAS Q61X mutant solid tumors at the 36th EORTC-NCI-AACR Symposium. The company is also conducting a Phase 3 trial in NRAS-mutant melanoma. A virtual R&D update for investors is scheduled for October 24, 2024.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2024 | 12:09 pm

TCMD

Tactile Systems Technology, Inc. (NASDAQ:TCMD) announced positive results from a clinical trial using their Flexitouch device for lymphedema treatment. The study showed significant improvements in limb girth, cellulitis events, and skin hyperpigmentation over 52 weeks.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2024 | 12:07 pm

HRTX

Heron Therapeutics' stock is rising following the FDA's approval of its Prior Approval Supplement application for the ZYNRELEF vial access needle.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2024 | 12:07 pm

NVEE

NV5 Global, Inc. has announced a 4-for-1 stock split to increase accessibility for employees and investors, boost liquidity, and align interests.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2024 | 12:06 pm

BNZI

Banzai International's shares are trading lower following the announcement of a $5 million private placement.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2024 | 12:06 pm